Once “proof of concept” that kisspeptin could be used as a trigger of oocyte maturation had been established, a further trial was conducted in 2015 to establish the safety and efficacy of kisspeptin in women at high risk of OHSS (16). This evidence concerns the gene KISS1 and ovarian hyperstimulation syndrome.